Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
View: Text | PDF
Research Article Neuroscience Vascular biology

Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation

  • Text
  • PDF
Abstract

Mutation of KRAS in endothelial cells (KRAS-ECs) leads to intracerebral hemorrhage (ICH) in brain arteriovenous malformation (bAVM), resulting in severe disabilities or even death. However, it is unclear what causes this hemorrhagic conversion of bAVMs. Here, using a locally established, clinically relevant sporadic bAVM mouse model, created by overexpressing mutant KRAS (KRASG12V) in brain ECs, we demonstrate that KRAS-ECs act as trigger for activation of microglia (MG) and infiltration of macrophages (Mϕ). Using a 3-dimensional immunostaining approach with cleared human and mouse bAVM tissues, we demonstrate an abundance of MG/Mϕ around the bAVM nidus. The presence of MG/Mϕ was correlated to the blood-brain barrier leakage in bAVM areas. Time-lapsed intravital imaging in Cx3cr1-gfp;Ccr2-rfp reporter mice demonstrated the dynamic activation of MG and infiltration of Mϕ toward mutant KRASG12V–modified dysplastic vessels. Importantly, a time-course analysis showed that these activated MG and infiltrated Mϕ are present around the bAVMs prior to hemorrhagic conversion, and controlled depletion of MG/Mϕ reduced ICH incidence in bAVMs. Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRASG12V-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in patients with bAVM.

Authors

Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park

×

Figure 6

Minocycline reduces activation of MG and recruitment of Mϕ toward bAVM territories in KRASG12V/bEC mice.

Options: View larger image (or click on image) Download as PowerPoint
Minocycline reduces activation of MG and recruitment of Mϕ toward bAVM t...
(A) KRASG12V/bEC mice received daily minocycline for 4 weeks starting 2 weeks after AAV-BR1-KRASG12V injection, and then mice were imaged with T2*-weighted MRI and brains were analyzed at 6 weeks. (B) Representative immunofluorescence images showing attenuated clustering of Cx3cr1-GFP+ MG and Ccr2-RFP+ Mϕ around CD31+ (vessel, cyan) bAVM territory in KRASG12V/bEC mice treated with minocycline compared with PBS. Scale bar: 50 μm. (C and D) Bar graphs quantifying numbers of Cx3cr1-GFP+ MG for total, ramified, bushy, and amoeboid based on morphology assessment (C) or total numbers of Ccr2-RFP+ Mϕ (D) in the bAVM territory between KRASG12V/bEC mice treated with minocycline or PBS. Unpaired, 2-tailed t test. ***P < 0.001. Each dot indicates a randomly selected ROI (n = 9–10) obtained from mice (n = 5 per group). (E) KRASG12V/bEC mice received minocycline once every 2 days, 4 times in total, starting 5 weeks after AAV-BR1-KRASG12V injection. The mice were observed with intravital imaging before and after the treatment. (F and G) Representative immunofluorescence images showing reduced clustering of Cx3cr1-GFP+ MG and Ccr2-RFP+ Mϕ in WGA-CF405–labeled dysplastic bAVM vessels in KRASG12V/bEC mice treated with minocycline (G) compared with PBS (F). Scale bar: 50 μm. (H–K) Bar graphs quantifying Cx3cr1-GFP+ MG (H and I, fluorescent pixel area) and Ccr2-RFP+ Mϕ (J and K, count of RFP+ cells) around dysplastic bAVM vessels. Individual ROIs were compared between pre- and posttreatment results for PBS- and minocycline-treated groups, respectively. A traced ROI compared between time points highlights the rapid reduction of GFP- and RFP-expressing cells following treatment with minocycline. Unpaired, 2-tailed t test. **P < 0.01. Each dot indicates a randomly selected ROI (n = 5–8) obtained from mice (n = 3 per group). (L and M) Representative T2*-weighted MRI (L) and ITK-SNAP volumetric images (M) show that minocycline reduced the ICH lesions in KRASG12V/bEC mice. (N) Bar graphs quantifying ICH volume. Unpaired, 2-tailed t test. **P < 0.01. Each dot indicates the hemorrhagic volume of an individual mouse (n = 4–5 per group). NS, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts